Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 17/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 17/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 17/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16467967 | 0.84 | HSD11B1 (0.48) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL16468337 | 0.84 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL12791455 | 0.82 | HSD11B1 (0.47) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL13016393 | 0.82 | HSD11B1 (0.52) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL12991729 | 0.82 | HSD11B1 (0.52) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL1747845 | 0.81 | TPSAB1 (0.46) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL21428432 | 0.81 | LMNA (0.47) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL769896 | 0.80 | TPSAB1 (0.49) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL8275268 | 0.79 | TPSAB1 (0.51) | TPSAB1TPSD1TPSG1PRSS1F2 | |
| SCHEMBL21428419 | 0.79 | LMNA (0.50) | TPSAB1TPSD1TPSG1PRSS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | TPSAB1 3073/4885TPSD1 3640/4885TPSG1 3411/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | TPSAB1 1944/4885TPSD1 1366/4885TPSG1 2558/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | TPSAB1 3073/4885TPSD1 3640/4885TPSG1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.